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Abstract
Objective: This study compared the participation in four faecal immunochemical testing-based screening programmes for
colorectal cancer in Flanders, France, Basque country and the Netherlands, to identify factors to further optimize faecal
immunochemical testing programmes.
Method: Background information and data on performance indicators were collected and compared for the four programmes.
Results: Invitation method, reminders, funding, faecal immunochemical testing cut-off and follow-up after positive faecal
immunochemical testing differed in the four programmes. In France, only an invitation letter is sent by mail, while the
sample kit must be collected from the general practitioner. In the other programmes, an invitation letter including the
sample kit is sent by mail. Participation rates vary substantially according to the method of invitation, with the highest partic-
ipation rates in the Netherlands (73.0%) and Basque country (72.4%), followed by Flanders (54.5%) and France (28.6%). Basque
country (92.8%) and France (88.4%), the two programmes with most active involvement of general practitioners in referral for
colonoscopy, had the highest participation rates for colonoscopy.
Conclusions: Large differences in screening participation observed between programmes according to the invitation method
used suggest that changes to the design of the programme, such as including the sample kit with the invitation, or active
involvement of GPs, might increase participation.
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Introduction
Many countries and regions have implemented
colorectal cancer (CRC) screening by faecal occult
blood testing (FOBT), in particular using faecal immuno-
chemical testing (FIT).1 Screening using FOBT is
recommended by European Union CRC screening guide-
lines.2 In France, a national population-based CRC
screening programme was initiated in 2002 using guaiac
FOBT, which was changed to FIT-based screening in
April 2015. FIT-based screening was introduced in 2009
in the Basque country (Spain), in 2013 in Flanders
(Belgium) and in 2014 in the Netherlands. As these four
European programmes are geographically close and con-
nected, and have recently been implemented, similar out-
comes with respect to CRC screening may have
been expected.
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The effectiveness of population-based screening pro-
grammes is driven not only by the sensitivity of the screen-
ing method but also by the availability of resources,
healthcare infrastructure and population preferences.
Population preferences in particular will be reflected in
participation rate. To determine the optimal screening
method for the population, pilot studies were performed
in the Basque country, Flanders and the Netherlands
before the initiation of the screening programmes. The
Basque Country pilot study in 2009 demonstrated a par-
ticipation rate with FIT screening of 64.3%.3 In Flanders,
the pilot study compared participation for two invitation
strategies: FIT directly sent by mail (52.3%), or invitation
only by mail and FIT to be collected from the general
practitioner (GP) (24.6%).4 In the Dutch pilot studies
comparing different screening methods, FIT screening
resulted in the highest CRC detection per invitee com-
pared with other screening methods, such as gFOBT, colo-
noscopy and sigmoidoscopy screening.5–7
Crucial to optimal screening performance is the organi-
zational structure of the programme, including pre-
invitation letters, reminders, and FIT mailing; however,
almost all studies of these aspects have been carried out
in trials.4,8,9 Actual performance in routine screening pro-
grammes may differ because many other factors are
involved, such as government-endorsement, organization
of healthcare systems and healthcare insurance.
Participation in the trial preceding the implementation of
the national Dutch programme, for example, was 60%,
which was significantly lower than the 71% achieved in
the first year of the national programme. It is unknown
how the different organizational aspects will affect individ-
uals residing in different countries, with different sociocul-
tural backgrounds.
This study aimed to identify similarities and differences
in the organizational structure of four large population-
based CRC screening programmes using FIT in France,
Basque country (Spain), Flanders (Belgium) and the
Netherlands, and then compare these with important pro-
gramme performance indicators of participation and
detection rates to infer relationships between organization-
al structure and these programme outcomes.
Methods
Information on year of initiation, target population, eligi-
ble population, screening interval, methods of invitation to
FIT screening and to colonoscopy following a positive
FIT, funding and executive organization of the four
screening programmes was collected. The target popula-
tion was defined for each population-based CRC screening
programme according to programme-specific policies. The
eligible population is the target population minus those
who are ineligible for screening based on exclusion criteria.
The eligible population was all individuals who should
have been invited in 2016. This number can deviate from
the total target population, because of biennial screening
or phased implementation of the national screen-
ing programme.
Data on performance indicators were extracted from
each of the national or regional screening databases. In
France, data were extracted from the database of French
Public Health Agency (Sante´ Publique France) and
Organized screening structure of the Big East region and
the Pyre´ne´es. Data from Flanders were extracted from the
screening database, the Belgian Cancer Registry and reim-
bursement data from the Health insurance companies. All
data from the Basque country were extracted from the
programme (Programa de Ca´ncer ColoRectal) database,
which is linked with medical records, population and hos-
pital cancer registries. All data from the Netherlands were
extracted from the national database for screening pro-
grammes (ScreenIT). Data on the invitees were collected
in France starting in April 2015 until June 2017. Data on
the invitees of 2016 were collected in the Basque country
until December 2017, and in Flanders and the Netherlands
until 30 June 2017.
Data were collected on the main performance indica-
tors: participation rate, FIT positivity rate, participation
rate in colonoscopy following positive FIT, detection rate
of CRC or advanced neoplasia (AN) per participant and
diagnostic yield. The definitions of performance indicators
were those recommended in the European Union CRC
screening guidelines.10
Participation rate was the number of persons sending
back the FIT sample divided by the number receiving an
invitation letter. For Flanders and France, persons were
only considered participants if they returned the FIT
sample within 12 months after the invitation. In the
Basque country, participants were those who returned an
assessable stool sample within six months following the
invitation. In the Netherlands, individuals were considered
participants until the date of the invitation of subsequent
screening round. Positivity rate was the number of persons
with a FIT result at or above the cut-off level, divided by
the number of persons with an assessable stool sample.
Participation rate colonoscopy was the number undergoing
a colonoscopy divided by the number with a positive FIT
result. Detection rate was defined as the number of persons
with AN detected during colonoscopy per participant. AN
was considered a relevant abnormality within a CRC
screening programme, and was defined as CRC or any
adenoma with histology showing 525% villous compo-
nent or high-grade dysplasia or adenoma with size
510mm. In Flanders, only adenomas with any villous
component and/or high-grade dysplasia were counted as
advanced adenoma, because no data were available on
adenoma size or the amount of villous components. In
the Basque country, in addition to histology, dysplasia
and size, having 53 adenomas was also considered as
advanced adenoma. Diagnostic yield of the programme
was defined as the number of persons with AN detected
during colonoscopy divided by all individuals who
received an invitation. In Flanders, data of colonoscopy
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yield were not linked to the date of invitees of the pro-
gramme. The denominator can contain individuals invited
in previous year.
The organizational structures of the four programmes
were compared using thematic analysis to identify similar-
ities or differences. Outcomes of the performance indica-
tors for each of the programmes were then compared. To
rule out the possibility that the observed difference may be
related to cultural differences between populations rather
than organizational differences, the programme of Basque
country in Spain was compared with the Basque country
in France, as these two regions are very close with respect
to geographical location and cultural background. The
different subgroups were compared using chi-squared
test. This test was performed using R version 3.5.0.
Results
The age range of the target populations differed, with
France and the Basque country having the lowest starting
age of 50 and the Basque country having the lowest
stopping age of 69 (Table 1). All four programmes used
a two-year screening interval. Exclusion criteria prior to
invitation differed among the four programmes. In the
Netherlands, persons are only excluded based on a positive
FIT result of previous screening round (Table 1). France,
Flanders and Basque country all excluded individuals with
history of CRC, proctocolectomy and recently performed
colonoscopy before invitation. France and Flanders also
excluded individuals with a recently performed FIT test.
Additionally, the Basque country excluded individuals
with severe or terminal illness.
Methods of invitation also differed among the four pro-
grammes. The eligible population in France received an
invitation letter to collect the FIT sample kit at the GP.
In Flanders, the invitation included the FIT sample kit. In
the Basque country and the Netherlands, a pre-invitation
letter was sent, followed by an invitation letter including
the FIT sample kit. All four screening programmes used a
reminder letter, but all at different time points, ranging
from 30 days (Basque country) to six months (France).
The programme in France sent two reminder letters. All
four programmes used different cut-offs for a positive FIT
and referral to colonoscopy: in Flanders, 15 mgHb/g
faeces; the Basque country, 20 mg Hb/g faeces; France,
30 mgHb/g faeces and the Netherlands, 47 mgHb/g faeces
(Table 1).
Among the four programmes, 18.9 million individuals
were invited to participate in FIT screening. The highest
participation rate was observed in the Netherlands
(73.0%), followed by the Spanish Basque country
(72.4%), Flanders (54.5%) and France (28.6%,
p<0.001). Because of the different FIT cut-off levels
used, the positivity rate differed between the four pro-
grammes, from 4.7% in France to 6.7% in Flanders
(p<0.001). The participation rate for colonoscopy fol-
lowing a positive FIT result was 92.8% in the Basque
country, 88.4% in France, 81.9% in Flanders and
82.8% in the Netherlands (p <0.001). Detection rate
for AN per participant was highest in the Netherlands
(2.3%) and lowest in Flanders (1.0%). Diagnostic yield
for AN per invitee was highest in the Basque country
(1.6%) and lowest in France (0.4%, p <0.001). Figure
1 shows the impact of FIT participation rate, positivity
rate and colonoscopy participation rate on the diagnostic
yield. This shows that programmes with the highest FIT
participation rate have the highest diagnostic yield, but
this is less visible for the positivity rate and colonoscopy
participation rate.
In the comparison of the French with the Spanish
Basque country, despite cultural similarities, differences
in screening performance indicators were observed
(Table 2). The participation rate in the Spanish part was
72.4%, 2.5 times as high as in the French part, with 24.6%
(p <0.001) (Table 3). Participation rate to colonoscopy
was high in both the Spanish and the French part
(92.8% and 87.4%, respectively; p¼0.37).
Discussion
Large differences in screening participation were observed
between programmes, in line with the invitation method
used. There are several possible explanations. First, send-
ing the FIT home is more effective than having it collected
at the GP. Almost all studies show a large increase in
participation when including the FIT sample kit with the
invitation.8,11–13 One Italian study showed only a modest
increase in participation, but this study was performed in
previously screened individuals (used to another screening
strategy).14 One French study showed low uptake rates
when directly mailing the FOBT.14 This inconsistency
may be due to the test modality, gFOBT instead of FIT,
resulting in lower participation rates.15
A second explanation for a higher FIT participation
may be the advanced notification letter, as illustrated by
the higher participation rate in the Spanish Basque coun-
try and the Netherlands. However, this will only explain a
small proportion of the total difference, as studies have
shown that sending a pre-invitation letter results in a
three percentage point increase.9,16 Only one study from
Australia showed a higher increase, nine percentage
points, when a pre-invitation letter was sent.17 The
higher participation with both direct mailing and the
pre-invitation letter is in line with a recent systematic
review.18 However, one large difference was that GP
involvement improved participation. This has also been
shown in France, with an increase of 4% if GPs were noti-
fied of the screening status of their patients so that they
could actively promote CRC screening to non-partici-
pants.8 We showed the opposite in this study; in a country
that sends out the FIT by mail with no involvement of
GPs, such as the Netherlands, participation rates were
very high, while in a country with active involvement of
GPs, such as France, participation rates were substantially
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lower. We hypothesize that GP endorsement can have a
positive impact on participation, as long this requires no
effort for the participants. This is in line with findings of
the CRC screening programme in England, which showed
an increase in participation if the invitation letter was
added with a GP endorsement banner.19
Our analysis of the two Basque regions in France and
Spain showed that very similar cultures can have very dif-
ferent rates in screening participation, and that culture
may not be the driving factor of performance differences
between programmes, although we cannot rule out cultur-
al differences completely. We know from the literature
that cultural difference in screening attitude is also
observed in the participation rates of other cancer screen-
ing programmes. In 2016, for example, participation in
breast cancer screening was also lower in Flanders
(51.9%) than in the Netherlands (77.6%) and the Basque
country (80.1%), with France having the lowest participa-
tion rate (50.7%).20–22 The participation rate for breast
cancer screening in France is similar to Flanders, while
there is a much larger difference in participation rate for
CRC screening. Gender cannot explain this difference, as
both men and women show a similar pattern in participa-
tion. This again reflects the negative impact of using a
different invitation method in France for FIT-
based screening.
Participation rate to follow-up colonoscopy was high in
all four screening programmes, although slightly below the
recommended 85% in the Netherlands and Flanders. We
hypothesize that higher participation to follow-up colo-
noscopy in Basque country and France may be the result
of the active involvement of GPs during the screening pro-
cess. In both countries, GPs play an active role in selecting
the population eligible for FIT screening, at collection of
the screening test, at follow-up after a negative FIT, or in
defining the eligible population by excluding those with
severe comorbidity from invitation. Consequently, those
participating in FIT screening are all healthy enough to
undergo follow-up colonoscopy. Conversely, it may also
explain the lower participation to colonoscopy in the
Netherlands, as there is no exclusion of individuals based
on co-morbidities or medical history. Active involvement
of GPs after positive FIT only for referral to colonoscopy,
without involvement in the total screening process, will be
less effective.8 Reimbursement differences for colonoscopy
do not seem to explain participation differences. Although
in the Basque country, the colonoscopy is free of charge,
participation in France was only slightly lower, while
French individuals may have significant expenses which
have to be paid from personal funds. One explanation
may be that in France, only the most motivated individu-
als collect the FIT sample kit at their GP practice, and they
may thus also be more motivated to attend colonoscopy in
case of a positive FIT.
Positivity rate differed for all four programmes, due to
three important reasons: cut-off level of the FIT, target
age group and screening round (first or subsequent
round).23 Higher cut-off level and subsequent screening
round will result in lower positivity rate, while higher
age will result in higher positivity rate. The same explan-
ations may partly hold for the difference in diagnostic
yield of the programme. Previous research showed that
using a higher FIT cut-off level will have a negative
Figure 1. Diagnostic yield of advanced neoplasia by FIT participa-
tion rate.
AN: advanced neoplasia; FIT: faecal immunochemical testing.
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Table 2. Performance indicators for France, Flanders, the Netherlands and Basque country.
France Flanders Netherlands Basque country p
Calendar year 2015–2016 2016 2016 2016
Age (years) 50–74 56–74 59–76 50–69
Target population 19,043,771 1,447,434a Unknown 273,084
Eligible population 16,701,387 830,665 1,543,223 239,601
Invited 16,701,387 571,034 1,457,976 229,380
% 100 68.7a 94.5 87.7
Number of participants 4,779,845 311,453 1,063,651 166,110 <0.001
Participation rate FIT % (95% CI) 28.6 (28.6–28.6) 54.5 (54.4–54.7)b 73.0 (72.9–73.0) 72.4 (72.2–72.6)
Men 27.8 53.1 71.1 70.0
Women 30.8 56.0 74.8 74.6
Screen round Any round First and second First and second First to fourth round
Cut-off level (Hb/g faeces) 30 mg 15 mg 47 mg 20 mg
Positivity rate % (95% CI) 4.7 (4.7–4.7) 6.7 (6.7–6.8) 5.4 (5.4–5.5) 5.2 (5.1–5.3) <0.001
Participation rate
colonoscopy % (95% CI)
88.9 (88.8–89.0)c 81.9 (81.4–82.4) 82.8 (82.5–83.1) 92.8 (92.3–93.4) <0.001
Detection rate
AN% (95% CI) 1.5 (1.5–1.5)c 1.0 (1.0–1.1) 2.3 (2.2–2.3) 1.9 (1.9–2.0) <0.001
CRC% (95% CI)
Diagnostic yield programme
0.31 (0.30–0.32)c 0.28 (0.26–0.30) 0.35 (0.34–0.36) 0.20 (0.18–0.22) <0.001
AN% (95% CI) 0.4 (0.4–0.4)c 0.6 (0.5–0.6) 1.6 (1.6–1.7) 1.4 (1.3–1.4) <0.001
CRC% (95% CI) 0.09 (0.09–0.09)c 0.15 (0.14–0.16) 0.25 (0.25–0.26) 0.15 (0.13–0.16) <0.001
Note: Advanced neoplasia was defined as CRC or any adenoma with histology showing525% villous component or high-grade dysplasia or adenoma with size
510mm. In Basque country, also 53 adenomas were considered AN. In Flanders, only adenoma with a villous component and/or high-grade dysplasia was
counted as advanced adenoma. There were no data available on the size or the amount of villous components in an adenoma. Detection rate: invitees with CRC
or AN per participant. Diagnostic yield: individuals with CRC or AN per invitees.
AN: advanced neoplasia; NA: not available; FIT: faecal immunochemical testing.
aEligible population in Flanders is the total number aged 56–74 for two years minus those excluded for invitation. Eligible population for 2016 only could not
be provided.
bCoverage by examination, also including opportunistic screening by FIT or colonoscopy, resulted in 65.5% of the target population to be screened.
cIn France, the participation rate of colonoscopy and number of colorectal cancers and advanced neoplasia was based on data from April 2015 until
December 2015.
Table 3. Outcome performance indicators Basque region.
Basque country in France Basque country in Spain p
Year 2016 2016
Age 50–74 50–69
Invited 45,923 229,380
Number of participants 11,293 166,110
Participation rate FIT % (95% CI) 24.6 (24.2–25.0) 72.4 (72.2–72.6) <0.001
Cut-off level (Hb/g faeces) 30 mg 20 mg
Positivity rate % (95% CI) 4.8 (4.4–5.2) 5.2 (5.1–5.3) 0.07
Participation rate follow-up
colonoscopy % (95% CI)
87.4 (84.4–90.0) 92.8 (92.3–93.4) 0.37
Detection rate
AN% (95% CI) 1.4 (1.2–1.7) 1.9 (1.9–2.0) <0.001
CRC% (95% CI)
Diagnostic yield
0.27 (0.19–0.39) 0.20 (0.18–0.22)
AN% (95% CI) 0.4 (0.3–0.4) 1.4 (1.3–1.4) <0.001
CRC% (95% CI) 0.07 (0.05–0.10) 0.15 (0.13–0.16)
AN: advanced neoplasia; FIT: faecal immunochemical testing.
Note: Advanced neoplasia was defined as CRC or any adenoma with histology showing525% villous component or high-grade dysplasia or adenoma with size
510mm. In Basque country, also 53 adenomas were considered AN. Detection rate: invitees with CRC or AN per participant. Diagnostic yield: individuals
with CRC or AN per invitees.
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impact on detection rates.24 Nevertheless, the impact of
positivity rate and colonoscopy participation rate on diag-
nostic yield was modest. Programmes with the highest FIT
participation rate still have the highest diagnostic yield,
regardless of their positivity rate or colonoscopy partici-
pation rate. This highlights the importance of high partic-
ipation rates to primary screening, as this will result in the
highest detection of AN. However, the difference in detec-
tion rates of AN is surprising, with the Netherlands having
high detection rates while having the highest cut-off. This
might be related to several factors: more incident screens
in France and Basque country (lower detection), more
prevalent screens in Flanders and the Netherlands, differ-
ence in age range (lower age, lower detection) and stricter
definition of advanced adenomas in Flanders
(lower detection).
Our study has three important strengths. It is the first
study that gives detailed information on organizational
structure of four large population-based programmes pro-
vided by representatives of each country. These details are
generally unknown, as key elements of CRC screening
programmes are only described in the local language
(Flemish, French, Spanish/Basque, Dutch). These details
can be used by other countries/regions considering CRC
screening and are valuable for policymakers. In addition,
our study contains the most recent outcomes of these large
population-based programmes, all using the same test
modality (FIT). Lastly, our study compared screening pro-
grammes of neighbouring countries with cultural similari-
ties and differences, and can thus address the impact of
cultural and organizational aspects on the uptake of
CRC screening.
The study has also some limitations. Comparing quality
indicators was challenging due to different definitions and
differences in cut-off level and number of screening
rounds. Unfortunately, we could not restrict the compar-
ison to first screen round data only, as not all programmes
have detailed information. In addition, data collection
may be of concern as, for example, France does not yet
have a centralized recording of quality indicators and does
not centrally collect data on diagnostic yield.
Our findings suggest that organizational structure, for
example, sending out the FIT, pre-invitation letter,
involvement of the GP in the screening programme and
colonoscopy referral, has an impact on the participation
rate to FIT and follow-up colonoscopy. These results
could be used to optimize each of the four screening pro-
grammes, or as an example for other organized FIT-based
CRC screening programmes. Possibilities for optimization
can differ for every organized programme, as healthcare
systems, funding of the colonoscopy and available resour-
ces also differ. Interventions for optimization will have
cost implications, and these results can therefore be used
to explore the additional benefits and costs for each pro-
gramme. France has already begun to optimize the screen-
ing programme, by deciding to mail the FIT with the first
reminder, but only to those individuals who participated in
previous rounds. The study by Giorgi-Rossi et al. suggests
that these individuals may not be the best target.25
Although posting the FIT and actively approaching
FIT positives for the colonoscopy seems to be most effec-
tive, this may be considered an infringement of free will.26
The goal of the screening programmes should not be high
participation, but the level of informed choice, although
infringement of free will should be considered in the light
of the strength of the recommendation. For CRC screen-
ing, and in particular for colonoscopy in FIT positives, the
evidence for net benefit is considered strong, and we can
presume that the vast majority would weigh the balance of
benefits and harm in the direction of having the interven-
tion.27 Moreover, there is no indication that high partici-
pation in the Netherlands, for example, results in a lower
level of informed choice.28,29 Besides these ethical consid-
erations, there is also a remaining difference in participa-
tion that cannot be explained by the organizational
structure and is difficult to unravel. This difference seems
to be a difference in attitude towards screening in general
between the different regions or countries, and it is unclear
how this arises or how it can be solved.
Conclusion
This study shows that there is large variability in the
design of these screening programmes, and that pro-
grammes with more evidence-based interventions in place
(e.g. mailed-out FIT, pre-invitation and reminder letters)
experience significantly higher screening participation than
those without. Active involvement of GPs may result in
slightly higher participation with colonoscopy after a pos-
itive FIT result, but should not come at the expense of
extra barriers to collect the FIT, which can dramatically
reduce primary screening participation.
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